Nexletol

Chemical Namebempedoic acid
Dosage FormTablet (oral; 180 mg)
Drug ClassInhibitors
SystemCardiovascular
CompanyEsperion
Approval Year2020

Indication

  • Nexletol is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Last updated on 10/20/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nexletol (bempedoic acid) Prescribing Information2020Esperion